verapamil / Generic mfg. - LARVOL DELTA

Vestibular migraine vs. migraine only: integrated transcriptome-clinical profiling reveals shared inflammation and divergent metabolic pathways for targeted therapy. (PubMed, Eur J Med Res) - "VM and MO share overlapping clinical and pathogenic features, particularly inflammation and metabolic dysregulation. CXCL8 serves as a shared biomarker, and NSAIDs, vitamin A, and verapamil may offer therapeutic benefits. The heightened inflammatory activation in VM suggests it could represent an advanced stage of MO, emphasizing the importance of early intervention in migraine progression."

Journal • CNS Disorders • Depression • Inflammation • Metabolic Disorders • Migraine • Mood Disorders • Pain • Psychiatry • Sleep Disorder • CXCL8 • IL17A

Efficacy and Safety of HB-1 for Panic Disorder (clinicaltrials.gov) - P2 | N=240 | Recruiting | Sponsor: Honeybrains Biotech LLC | Trial completion date: Feb 2026 ➔ Feb 2027 | Trial primary completion date: Jan 2026 ➔ Jan 2027

Trial completion date • Trial primary completion date • CNS Disorders • Mood Disorders • Psychiatry

Intracoronary adjunctive therapies for ST-elevation myocardial infarction: a network meta-analysis of trials. (PubMed, Eur Heart J Cardiovasc Pharmacother) - "Adjunctive IC treatments during primary PCI do not influence hard clinical outcomes compared to conventional therapy within a mean 8-month follow-up, although several of them lead to an improvement in surrogate endpoints of CMVO."

Journal • Retrospective data • Cardiovascular • Congestive Heart Failure • Heart Failure • Myocardial Infarction • Thrombosis • Ventricular Tachycardia

Predicting xenobiotic metabolism: a computational approach mining LC-MS/MS data with SIRIUS and BioTransformer. (PubMed, Arch Toxicol) - "We challenged our workflow to the analysis of human metabolites from 6 well-known drugs, administered to primary human hepatocytes and human liver microsomes: amitriptyline (10 µM), carbamazepine (12.5 µM), cyclophosphamide (20 µM), fipronil (20 µM), phenytoin (50 µM), and verapamil (6 µM). This strategy proved efficient in accelerating the study of drug metabolism, potentially avoiding tedious manual metabolite identification. In sum, we demonstrate that this computational workflow holds potential in automating metabolite identification, expanding metabolite coverage, and elucidating metabolites of newly developed drugs."

Journal

Aminated Quinolinequinones With EDG(s) as a Prostate Cancer Inhibitor: Mechanistic Insights and Pharmacokinetic Limitations. (PubMed, Chem Biodivers) - "In metabolic stability assays using human liver microsomes, AQQ6 exhibited relatively low intrinsic clearance (Clint) and an improved half-life (T1/2) compared to verapamil. However, pharmacokinetic studies in rats indicated poor oral bioavailability (%F = 4.2), likely due to extensive hepatic metabolism in rat liver microsomes. Molecular dynamics simulations targeting MAPK8, the protein likely involved in AQQ6 activity, were conducted to elucidate molecular-level binding interactions."

Journal • PK/PD data • Breast Cancer • Colon Cancer • Colorectal Cancer • Genito-urinary Cancer • Hematological Malignancies • Leukemia • Oncology • Prostate Cancer • Solid Tumor • MAPK8

Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study (clinicaltrials.gov) - P=N/A | N=13656 | Not yet recruiting | Sponsor: First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

New trial • Real-world evidence • Cardiovascular • Infectious Disease • Pneumonia • Respiratory Diseases

Vasospasm following resection of olfactory groove meningiomas via orbitozygomatic craniotomy: illustrative cases. (PubMed, J Neurosurg Case Lessons) - "Postoperative vasospasm is an important but often overlooked complication following anterior skull base meningioma resection. Early recognition and aggressive management with intra-arterial therapy can mitigate ischemic complications. Neurosurgeons should maintain high suspicion for vasospasm in the setting of neurological decline after tumor resection near the circle of Willis. https://thejns.org/doi/10.3171/CASE25641."

Journal • Brain Cancer • Cardiovascular • Hematological Disorders • Meningioma • Oncology • Ophthalmology • Solid Tumor • Subarachnoid Hemorrhage

Quinidine-Induced Microvolt Electrocardiographic Alternans. (PubMed, Annu Int Conf IEEE Eng Med Biol Soc) - "The study population belongs to the "ECG Effects of Ranolazine, Dofetilide, Verapamil, and Quinidine in Healthy Subjects" database. Furthermore, ECGA magnitude seemed to reveal transient changes better than amplitude, resulting in more post-dose time points, especially in the range 3.5-7 hours after quinidine administration, at which ECGA was statistically different than at the pre-dose time point. Thus, ECGA appears to disclose the higher risk of arrhythmia associated with quinidine.Clinical Relevance- The present study provides a contribution to guide therapy involving quinidine through the analysis of its proarrhythmic risk by electrocardiographic alternans."

Journal • Cardiovascular

Penile curvature management in Italy: a survey analysis by the Italian Society of Urology. (PubMed, Arch Ital Urol Androl) - "This nationwide survey reveals a significative heterogeneity in PC and PD management in Italy, with frequent reliance on off-label treatments and variable adherence to international guidelines. Economic limitations and regional differences appear to be a primary factor influencing clinical decisions and clinical practice. These findings underline the need for a major dissemination of evidence-based guidelines associated with national healthcare strategies aimed at standardized care and improving patient outcomes."

Journal • Erectile Dysfunction • Urology

Atrioventricular Block and Cluster Headache (SEVA) (clinicaltrials.gov) - P4 | N=60 | Active, not recruiting | Sponsor: Centre Hospitalier Universitaire de Nice | Recruiting ➔ Active, not recruiting | Trial completion date: Mar 2025 ➔ Sep 2027 | Trial primary completion date: Mar 2025 ➔ Sep 2025

Enrollment closed • Trial completion date • Trial primary completion date • Pain

Novel pyrimidine-artesunate hybrids overcome multidrug-resistance in non-small cell lung carcinoma through collateral sensitivity. (PubMed, Bioorg Chem) - "Computational docking study showed that 17a binds the verapamil-binding pocket of P-gp with greater affinity than dexverapamil (Dex-Ver). The P-gp mechanism and the difference in redox balance between sensitive and resistant NSCLC cells drive collateral sensitivity achieved by 15h and 17a. Overall, the study demonstrates that pyrimidine-artesunate hybrids selectively target MDR cancer cells, highlighting their potential to overcome drug resistance in cancer treatment."

Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Refractory chronic cluster headache: A new therapeutic option (EHF-EHC 2025) - "Acute therapy with oral zolmitriptan 5 mg, subcutaneous sumatriptan 6 mg, and oxygen were used, with moderate effect. Preventive treatment included prednisolone and occipital nerve block during exacerbations, and verapamil, both as monotherapy and in combination with topiramate and lithium in various regimens...Treating refractory chronic cluster headache is challenging, as it is highly disabling for the patient. Although other therapies targeting CGRP have not shown clear benefit in clinical trials, especially in chronic forms, atogepant may offer a promising alternative."

Anorexia • Cardiovascular • Chronic Cluster Headache • CNS Disorders • Constipation • Gastroenterology • Gastrointestinal Disorder • Hypertension • Migraine • Pain

Use of gepants in the acute treatment and bout modulation of cluster headache: A retrospective case series (EHF-EHC 2025) - "Notably, no traditional preventive therapies (e.g., verapamil, corticosteroids) were used during the reported bout Retrospective case series of six CH patients who used gepants during a recent cluster bout...Rimegepant 70 mg (every other day, 16–28 days) was used by four patients; two used atogepant 60 mg/day (28 days)...Their efficacy in chronic CH remains uncertain. These preliminary findings warrant confirmation in prospective, controlled studies"

Retrospective data • CNS Disorders • Constipation • Gastroenterology • Gastrointestinal Disorder • Migraine • Pain

Challenging the criteria: A case of unclassifiable trigeminal autonomic-like headache (EHF-EHC 2025) - "Frovatriptan provided fast relief, although some residual pain persists for up to 1 day. Indomethacin was tried but rapidly dismissed due to side effects...Despite the atypical pain duration, the presence of prominent autonomic signs and the partial response to Verapamil favours a diagnosis within the trigeminal autonomic cephalalgia spectrum, highlighting the diagnostic complexity of these entities. Disclosure:the patient gave her informed consent to publish her details."

Clinical • Mood Disorders • Pain

Efficacy of pharmacological and non-pharmacological interventions in the prophylaxis cluster headache: A systematic review (EHF-EHC 2025) - "Objectives include assessing pharmacological treatments like galcanezumab, verapamil, lithium, and non-pharmacological options such as non-invasive vagus nerve stimulation (nVNS). Galcanezumab and nVNS have the strongest evidence for reducing attack frequency and severity. More long-term, large-scale studies are needed to confirm findings and tailor treatments."

Clinical • Review • Pain

Cluster headache in the emergency department (EHF-EHC 2025) - "In the remaining patients, the most used options were corticosteroids (12.9%), corticosteroids and verapamil (11.9%) and verapamil (6.9%). The months with the most episodes were July, January and December with 13.9%, 11.9% and 10.9% of visits respectively, and those with the least were June and October with 4% and 5% respectively. Most cases do not receive urgent care by Neurology, which results in worse therapeutic regimens, less use of preventive drugs at discharge and lack of subsequent follow-up."

Anesthesia • Pain

Treatment pattern and reasons for discontinuing preventive treatment in cluster headache: A prospective cohort study (EHF-EHC 2025) - "Proportionally, the second-line treatments with lithium or topiramate were discontinued due to intolerance in nearly half of the patients. Effective therapeutic prevention of cluster headache is hindered by intolerance and insufficient efficacy of the preventatives. Verapamil remains effective over time for a subgroup of initial responders, but our findings underscore the need for more tolerable and effective prophylactic medicine in the treatment of cluster headache."

Clinical • Pain • Preventive care

Atogepant in episodic cluster headache: A case report on efficacy and tolerability (EHF-EHC 2025) - "Previous preventive therapies with high-dose verapamil (240 mg twice daily) and topiramate (50 mg/day) offered limited benefit, with 1-2 bouts of the disease each year. Although adverse effects limited its use in this case, the rapid and complete response warrant further investigation. Controlled studies are warranted to assess its efficacy, safety and potential role in the management of cluster headache."

Case report • Clinical • Anorexia • Pain

Altered clock function in primary skin fibroblasts cultures derived from cluster headache patients (EHF-EHC 2025) - "Verapamil treatment resulted in a less robust re-entrainment as compared to controls, and prolonged the circadian period. Our data points to a less robust molecular clock in primary fibroblasts isolated from CH patients as compared to controls, and verapamil treatment makes cell populations more susceptible to external entrainment."

Pain • ARNTL • BMAL1 • CLOCK

Audit / service evaluation Verapamil : Clinical and ECG monitoring in patients with cluster headache (EHF-EHC 2025) - "Our study highlights the need for safer, more consistent verapamil prescribing. We are developing a regional pathway, checklist, and dedicated clinics for new patients."

Clinical • Cardiovascular • Pain

Genome-wide identification of ABC transporters and their contribution to triflumezopyrim susceptibility regulated by microRNAs in Laodelphax striatellus. (PubMed, Pestic Biochem Physiol) - "Synergism studies revealed that verapamil significantly increased triflumezopyrim toxicity against L. striatellus...These results demonstrate that PC-5p-3991_515 modulates triflumezopyrim tolerance in L. striatellus by targeting ABCG11 and ABCH1. This study enhances the understanding of transcriptional regulation of triflumezopyrim tolerance mediated by miRNA-ABC transporter and has guiding significance for the management of L. striatellus and other pests."

Journal • ABCC2 • ABCG2

Unmasking Hemiplegic Migraine: A Diagnostic Dilemma in the Shadow of Stroke. (PubMed, Cureus) - "A diagnosis of sporadic HM was made after a thorough history by the primary care provider and managed conservatively with verapamil. This case highlights the critical role of primary care in synthesizing clinical information and history to establish an accurate diagnosis, underscoring the need for detailed patient evaluation. Raising awareness of HM as part of the differential diagnosis is vital after ruling out life-threatening conditions through imaging and clinical evaluation."

Journal • Cardiovascular • CNS Disorders • Depression • Migraine • Pain • Psychiatry

Magnesium in Aconitine-Induced Electrical Storm-Mechanism Yes, Mandate No. (PubMed, Ann Noninvasive Electrocardiol) - "We propose a practical, evidence-based algorithm emphasizing: (1) first-line flecainide 2 mg/kg IV, (2) magnesium sulfate adjunct targeting serum levels of 1.5-2.0 mmol/L, (3) aggressive calcium repletion to > 1.00 mmol/L, (4) early high-flux hemoperfusion within 6 h, and (5) VA-ECMO for refractory cases. Verapamil, diltiazem, and β-blockers as sole agents should be explicitly avoided."

Journal • Review • Cardiovascular • Hypotension

High MDR1 expression in rheumatoid arthritis is associated with increased MMP-3 levels and use of bDMARDs: potential independence of JAK inhibitors from MDR1. (PubMed, Rheumatology (Oxford)) - "High MDR1 expression correlates with elevated MMP-3 levels and more frequent bDMARDs use. JAK inhibitors remain effective regardless of MDR1 status, potentially bypassing MDR1-mediated cellular drug resistance in RA."

Journal • Immunology • Inflammatory Arthritis • Orthopedics • Pain • Rheumatoid Arthritis • Rheumatology • ABCB1 • ICAM1 • MMP1 • MMP3

Verapamil Suppresses the Development of Resistance Against Anti-Tuberculosis Drugs in Mycobacteria. (PubMed, Int J Mol Sci) - "The results show that verapamil significantly reduces the resistance frequency of multiple antimycobacterial agents, including the DNA gyrase inhibitor moxifloxacin, the protein synthesis inhibitor streptomycin, and the RNA polymerase inhibitor rifampicin in Mycobacterium smegmatis. These findings suggest that verapamil exerts a dual role by interfering with efflux pump functionality and by reducing the probability of chromosomal mutations. The combination of these properties may underlie the promise of verapamil as adjuvant to enhance the effectiveness of current antimycobacterial chemotherapy."

Journal • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis